Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- N/A
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE3
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- Status
- RECRUITING
- Phase
- NA
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- Status
- RECRUITING
- Phase
- PHASE2
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
- Status
- RECRUITING
- Phase
- PHASE2
64Cu-LLP2A for Imaging Hematologic Malignancies
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Epco, Zanu, Ritux for R/R FL or MZL
- Status
- RECRUITING
- Phase
- PHASE2
SynKIR-310 for Relapsed/Refractory B-NHL
- Status
- RECRUITING
- Phase
- PHASE1
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
- Status
- RECRUITING
- Phase
- N/A
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
- Status
- RECRUITING
- Phase
- PHASE2
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
- Status
- RECRUITING
- Phase
- NA
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
- Status
- RECRUITING
- Phase
- PHASE2